India ruling on cancer drug to be challenged

Order forcing Bayer to license its product to local company has huge repercussions for pharmaceutical giants.



    A patent ruling in India is forcing German drug giant Bayer to license its anti-cancer medicine to an Indian company, Natco.

    This will slash the price of the drug in India by up to 97 per cent. Bayer insists it will fight the ruling although Natco will be paying it six per cent royalty on the sales of Nexavar.

    This is the first time such a ruling has been made in India and has massive repercussions for drug giants and their patents globally.

    Prerna Suri reports from New Delhi.

    SOURCE: Al Jazeera


    YOU MIGHT ALSO LIKE

    Interactive: Coding like a girl

    Interactive: Coding like a girl

    What obstacles do young women in technology have to overcome to achieve their dreams? Play this retro game to find out.

    Heron Gate mass eviction: 'We never expected this in Canada'

    Hundreds face mass eviction in Canada's capital

    About 150 homes in one of Ottawa's most diverse and affordable communities are expected to be torn down in coming months

    I remember the day … I designed the Nigerian flag

    I remember the day … I designed the Nigerian flag

    In 1959, a year before Nigeria's independence, a 23-year-old student helped colour the country's identity.